For CTA and kaolin-intake studies, male Wistar rats (Janvier Labs, WistarRjHan:WI) were used
Current FDA-approved weekly injectable GLP-1 options include: Ozempic (semaglutide, Novo Nordisk) for type 2 diabetes Wegovy (semaglutide, Novo Nordisk) for chronic weight management Mounjaro (tirzepatide, Lilly) for type 2 diabetes Zepbound (tirzepatide, Lilly) for chronic weight management Rybelsus (oral semaglutide, Novo Nordisk) for type 2 diabetes Foundayo (orforglipron, Lilly) oral, for weight management (approved April 2026) For patients who struggle specifically with weekly injections, the most practical currently available option is Foundayo (orforglipron) an oral pill requiring no injection at all
Recommended Usage: Full Face Mesotherapy: Option 1: Non-crosslinked HA (1CC) + Glutanex Glow (1CC) + Lidocaine (0.5CC). Option 2: Glutanex Glow (3CC) + Lidocaine (0.5CC)
The following guidelines represent standard approaches based on available research and community experience
There is some evidence that GLP-1 drugs may be associated with increased suicidal thoughts in certain patients